October 25, 2011
Wilhelm Stahl, Ph.D. Joins Relypsa as Senior Vice President, Pharmaceutical Operation

June 28 , 2011
Relypsa Begins Treatment in AMETHYST-DN Trial of RLY5016 for Hyperkalemia in Diabetic Nephropathy Patients with Chronic Kidney Disease

May 23, 2011
Relypsa Announces Presentation of Positive Phase 2 Results for RLY5016 at American Society of Hypertension Meeting

May 19, 2011
Relypsa Adds Key Leadership Positions to Support Late-Stage Development and Pre-Launch Commercial Activities

September 15, 2010
Positive Phase 2 Data for RLY5016 Presented in Late-Breaker Session at Heart Failure Society of America Meeting

September 13, 2010
Relypsa Raises $70 Million in Series B - Financing; Funds to Support Late-Stage Development of RLY5016 - New Board Members Announced

August 29, 2010
ESC 2010: Hot Line I: New oral potassium binder lowers potassium levels in patients with heart failure and heart failure with chronic kidney disease

June 16, 2010
Relypsa Initiates Open-Label Phase 2 Clinical Study of RLY5016 for the Management of Hyperkalemia

June 16, 2010
Relypsa Appoints Claire J. Lockey Vice President, Regulatory Affairs

October 7, 2009
Relypsa Initiates Phase 2b Clinical Trial of RLY5016 for the Prevention of Hyperkalemia in Heart Failure Patients

January 9, 2008
Relypsa appoints Ronald A. Krasnow Senior Vice President, Intellectual Property and Chief Patent Counsel

October 29, 2007
Relypsa formed with $33 Million Series A Funding to discover and develop polymeric drugs